Members of the aspartic protease family have been implicated in cancer progression. The aspartic protease napsin A is expressed in type II cells of the lung, where it is involved in the processing of surfactant protein B (SP-B). Napsin A is also expressed in kidney, where its function is unknown. Here, we examined napsin A mRNA expression in human kidney tissues using in situ hybridization. Whereas strong napsin A mRNA expression was observed in kidney proximal tubules, expression was detected in only one of 29 renal cell carcinomas. This result is consistent with previous observations of loss of napsin A expression in high-grade lung adenocarcinomas. We re-expressed napsin A in the tumorigenic HEK293 kidney cell line and examined the phenotype of stably transfected cells. Napsin A-expressing HEK293 cells showed an altered phenotype characterized by formation of cyst-like structures in three-dimensional collagen cultures. Napsin A-expressing cells also showed reduced capacity for anchorage-independent growth and formed tumors in SCID mice with a lower efficiency and slower onset compared to vector-transfected control cells. Mutation of one of the aspartic acid residues in the napsin A catalytic site inactivated enzymatic activity, but did not influence the ability to suppress colony formation in soft agar and tumor formation. The mutation of the catalytic site did not affect processing, glycosylation or intracellular localization of napsin A. These data show that napsin A inhibits tumor growth of HEK293 cells by a mechanism independent of its catalytic activity.
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Members of the aspartic protease family have been implicated in cancer progression. The aspartic protease napsin A is expressed in type II cells of the lung, where it is involved in the processing of surfactant protein B (SP-B). Napsin A is also expressed in kidney, where its function is unknown. Here, we examined napsin A mRNA expression in human kidney tissues using in situ hybridization. Whereas strong napsin A mRNA expression was observed in kidney proximal tubules, expression was detected in only one of 29 renal cell carcinomas. This result is consistent with previous observations of loss of napsin A expression in high-grade lung adenocarcinomas. We re-expressed napsin A in the tumorigenic HEK293 kidney cell line and examined the phenotype of stably transfected cells. Napsin A-expressing HEK293 cells showed an altered phenotype characterized by formation of cyst-like structures in three-dimensional collagen cultures. Napsin A-expressing cells also showed reduced capacity for anchorage-independent growth and formed tumors in SCID mice with a lower efficiency and slower onset compared to vector-transfected control cells. Mutation of one of the aspartic acid residues in the napsin A catalytic site inactivated enzymatic activity, but did not influence the ability to suppress colony formation in soft agar and tumor formation. The mutation of the catalytic site did not affect processing, glycosylation or intracellular localization of napsin A. These data show that napsin A inhibits tumor growth of HEK293 cells by a mechanism independent of its catalytic activity. The aspartic protease family includes several physiologically important enzymes such as pepsin, chymosin, renin, gastricsin, cathepsin D and cathepsin E. Some members of this protease family, in particular cathepsin D and cathepsin E, have been implicated in cancer progression. High cathepsin D expression is associated with shorter disease-free and overall survival in patients with breast cancer. 1, 2 In patients with ovarian or endometrial cancer, cathepsin D expression has been reported to be associated with tumor aggressiveness. 3, 4 Transfection of low-metastatic tumor cells with wild-type human cathepsin D results in stimulation of tumor growth and increased propensity for experimental metastasis. 5 Interestingly, the catalytic activity of cathepsin D is not required for stimulation of tumor growth. 6 Cathepsin E expression has been reported to be a prognostic marker in bladder cancer. 7 Cathepsin E has also been suggested to promote tumor growth independent of its catalytic activity. 8 Napsin A is an aspartic protease expressed in the lung and the kidney. [9] [10] [11] [12] Napsin A is expressed in type II cells in lung alveoli and is capable of cleaving the proform of surfactant protein B (SP-B) expressed in this cell type. 13, 14 Studies using siRNA showed that downregulation of napsin-A in type II cells results in inhibition of SP-B processing. 13, 14 Among the different types of lung cancers, only adenocarcinomas express napsin A, making napsin A a promising diagnostic marker for primary lung adenocarcinomas. [15] [16] [17] Lung adenocarcinomas with a low differentiation grade express napsin A less frequently than more differentiated tumors, suggesting an inverse association between napsin A and tumor progression. 15, 16, 18 Napsin was first described in mouse kidney as a new member of the aspartic protease family (KAP; kidney aspartic protease). 9 A previous study reported napsin A localization to lysosomes in proximal tubules. 19 Napsin expression in kidney is first observed at embryonic day 13, preceding kidney tubulogenesis. 19 The function of napsin in the kidney remains unknown, but the pattern of embryonal expression raises the possibility that napsin may play a role in the differentiation of proximal tubules. 19 Considering the importance of lysosomal aspartyl proteases during carcinogenesis and the possible role of napsin during kidney differentiation, here we examined the expression of napsin A in renal carcinomas. Furthermore, we studied the effect of re-expressing napsin A in a tumorigenic kidney cell line. We report that napsin A suppresses anchorage-independent growth and tumor formation by a mechanism independent of its catalytic activity.
MATERIALS AND METHODS

In Situ Hybridization
Twenty-nine renal cell carcinoma tissues, from patients treated in the Karolinska Hospital from 1995 to 1998, were randomly selected. The tissues consisted of 10 grade I, 12 grade II and 7 grade III cancers. The study was approved by the local ethical committee. Formalin-fixed, paraffin-embedded tumor sections were deparaffinized with xylene, treated with proteinase K (1 mg/ml, 371C, 30 min), transferred to 0.1 M triethanolamine buffer (5 min) and treated with triethanolamine containing 0.25% acetic anhydride for 10 min. Sections were washed in 2 Â SSC, dehydrated and allowed to air-dry. After overnight hybridization (2 Â SSC, 50% formamide, 10% dextran sulfate, 551C) with an 35 S-labeled RNA probe (1.16 Â 10 5 c.p.m./ml), sections were washed (the most stringent step being 0.1 Â SSC, 15 min at 601C) and treated with RNase A (20 mg/ml, 371C, 30 min). Finally, the slides were dehydrated, air-dried, dipped in Kodak NTB emulsion, exposed for 7-14 days at 41C, developed and counter-stained with hematoxylin-eosin. The probes were made using T3 (antisense) and T7 (sense) RNA polymerase (Promega, Madison, WI, USA) from a pCMS-EGFP vector (Clontech, Palo Alto, CA, USA) containing an NheI/EcoRI napsin A full-length cDNA. Both sense and antisense probes were hybridized to all sections.
DNA Constructions
HA-tagged human napsin A cDNA was generated by polymerase chain reaction (PCR) using specific primers to human napsin A: 5 0 primer, agcgctagcatgtctccaccaccgctgct (primer N1); 3 0 primer, cgcgaattctcaagcgtagtctgggacgtcg tatgggtacccggggaactgcgcctgcg (primer N2). A PCR fragment was subcloned into pEGFP-N3 vector (Clontech) at NheI and ECoRI site. To generate a mutated napsin cDNA tagged with HA, PCR was performed using specific primers. To generate mutation of the catalytic site, the PCR-based overlap extension method was applied. 20 Primers were designed as follows: N-terminal fragment, 5 0 primer, primer N1; 3 0 primer, ccgtattcaggatggcagcacagccct; C-terminal fragment, 5 0 primer, catcctgaatacgggcacgtccctcatc; 3 0 primer, primer N2. To generate a control vector, the EGFP sequence was removed from pEGFP-N3 using restriction enzymes SalI and NotI and both ends were filled in using the Klenow fragment, followed by self-ligation. None of the constructs were fused with EGFP. All constructs were subjected to bi-directional sequencing.
Stable Transfectants
Cells were maintained at 371C in a 7% CO 2 atmosphere in DMEM (Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Invitrogen). Plasmids were transfected into HEK293 cells using LIPOFECTAMINE (Invitrogen). For stable expression, transfected cells were selected with G418 (Invitrogen) and G418-resistant colonies were analyzed for the expression of wild-type and mutant napsin A by immunoblotting with anti-HA antibody (clone 3F10; Roche Molecular Biochemicals, Mannheim, Germany).
Western Blotting
Samples were separated by electrophoresis in 12% polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were incubated in blocking solution (5% nonfat dry milk in PBS containing 0.05% Tween 20) for 1 h at room temperature and then incubated overnight with anti-HA antibody (clone 3F10; 100 ng/ml; Roche Molecular Biochemicals) or antibodies directed against mature SP-B (number 28031) or SP-B proprotein (number 55522). 21 The membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated anti-rat IgG (Pierce, Rockford, IL, USA) or HRP-conjugated anti-rabbit Ig (Amersham Biosciences, Little Chalfont, UK) for 1 h. The membranes were washed six times and peroxidase activity was developed by SuperSignal West Pico (Pierce) according to the manufacturer's instructions.
Cell Proliferation Assay
For each cell line, 1 Â 10 4 cells were seeded in 5 wells Â 5 rows of 96-well plates in 100 ml DMEM containing 10% FBS. After 24, 48, 72 and 96 h, cell proliferation was assayed using CellTiter 96
s Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer's instructions. After growth curves were drawn, cell doubling time was calculated using the log-phase growth rate: cell doubling time ¼ (2/the log phase growth rate for 24 h) Â 24 h.
Colony Formation in Soft Agar
Five hundred cells from each of the stably transfected cell lines were suspended in 2.5 ml of 0.35% (W/V) agar in DMEM/20% FBS and overlaid onto 0.5 ml of 0.5% (W/V) agar in DMEM/20% FBS in three wells of a 12-well plate. After 10 days, colonies with more than 20 cells were scored as positive using an inverted microscope.
Cell Culture in Collagen Gel
Five hundred cells were suspended in 1.5 ml of type I collagen gel solution containing 66% vitrogen 100 (Cohesion Technologies, Palo Alto, CA, USA), 1 Â DMEM, 0.004 g/l folic acid and 3.7 g/l sodium bicarbonate and overlaid onto 0.6 ml of collagen gel solution in a 12-well plate.
Tumor Growth in SCID Mice
Cells from each clone were suspended in PBS (2 Â 10 7 cells/ ml) and injected subcutaneously at the right and left Napsin A suppresses tumor growth T Ueno et al dorsal flanks of C.B-17/IcrCrl SCID mice (Charles River Laboratories, Sulzfeld, Germany) (100 ml per mouse). Five mice were injected with each clone. The tumor volume was measured daily until day 141 with a caliper rule. The tumors' major and minor diameters were measured and the volume was estimated at 4/3p Â (major radius) Â (minor radius) 2 . Mice were killed when the major diameter of the tumor had reached 2 cm. In all the experiments, the ethical guidelines for investigations in conscious animals were followed and the experiments were approved by the local Ethics Committee for Animal Research.
Deglycosylation
Cells were lysed in a denaturing buffer (PBS, 0.5% SDS, 1% b-mercaptoethanol) and boiled for 10 min. The supernatant was incubated for 1 h with endoglycosidases F (New England Biolabs, Beverly, MA, USA) as recommended by the manufacturer.
Immunoprecipitation
Cells were lysed in a lysis buffer (PBS, 20 mM EDTA, 1 mM PMSF, 1% Elugent (Calbiochem, Darmstadt, Germany)) at 41C for 30 min and centrifuged at 12 000 g at 41C for 20 min. The supernatant was incubated with anti-HA affinity matrix (Roche Molecular Biochemicals) at 41C overnight and the matrix was washed with the lysis buffer six times.
Proteolytic Activity of Napsin A Recombinant proSP-B lacking the entire 102 amino-acid C-terminal domain (SP-B DC ) was synthesized in the baculovirus system. The sequence encoding residues 1-279 of the human SP-B proprotein (SP-B DC ) was cloned in-frame with a six-residue C-terminal histidine tag and ligated into pVL1393 (BD Biosciences Pharmingen, San Diego, CA, USA). Recombinant baculovirus was produced by homologous recombination in Spodoptera frugiperda cells, as previously described. 22 Fresh monolayers of Trichoplusia ni cells were infected with plaque purified recombinant virus at an MOI of 2 and cultured in serum-free media for 72 h. Recombinant SP-B DC was purified from the culture media of infected insect cells by NTA affinity chromatography, under non-denaturing conditions, as previously described. 23 Purified SP-B DC was incubated with immunoprecipitates from the stable transfectants of control, napsin A or either mutant in an incubation buffer (0.1 M sodium acetate, 20 mM EDTA, pH 4.7) at 371C for 2 h.
Immunofluorescence Cells grown on coverslips were fixed (4.0% formaldehyde in PBS, pH 7.4, 10 min), permeabilized (0.1% Triton X-100 in PBS, 3 min) and blocked for 30 min in medium containing 5% normal goat serum. After rinsing with PBS, immunostaining was performed by incubating the cells with antibodies in the following order with rinsing between antibodies: anti-HA (2 ng/ml; clone 3F10; Roche Molecular Biochemicals), Cy3-conjugated anti-rat IgG (H þ L) (1:100; Jackson ImmunoResearch, West Grove, PA, USA), anti-LAMP-1 (1:200; BD Biosciences, Palo Alto, CA, USA) and fluorescein-conjugated anti-mouse IgG heavy and light chain (1:30; Calbiochem). Coverslips were mounted onto slides with VECTASHIELD Mounting medium with DAPI (H-1200, Vector Laboratories Inc., Burlingame, CA, USA). Cells were visualized by an immunofluorescence microscope (Axioplan 2 imaging, ZEISS). Cells in collagen gels were stained after digestion of collagen with 100 U/ml collagenase (Sigma-Aldrich Sweden AB, Stockholm, Sweden) for 15 min. Cells were fixed (4.0% formaldehyde in PBS, pH 7.4, 15 min), permeabilized (0.5% Triton X-100 in PBS, 15 min), incubated (0.5 mg/ml sodium borohydrate in PBS) and blocked for 30 min in medium containing 5% normal goat serum. After rinsing with PBS, immunostaining was performed as above.
RESULTS
Lack of Napsin A mRNA Expression in Renal Cell Carcinoma Napsin A mRNA expression was examined in normal and cancerous kidney tissue using in situ hybridization (Figure 1) . In normal kidney tissue, napsin A mRNA expression was observed in proximal convoluted and straight tubules and collecting ducts in agreement with previous reports (Figure 1a and b) . 12, 19 Twenty-nine renal carcinomas were 
Generation and Characterization of Cells Expressing
Wild-Type and Catalytically Defective Napsin A The observation of downregulation of napsin A in kidney tumors prompted us to generate kidney tumor cells that stably express napsin A. HEK293 is a tumorigenic cell line originally derived from human embryonic kidney cells by transfection of adenovirus type 5 DNA. 24 This cell line does not express a detectable amount of napsin A. 12 An HA-tagged cDNA napsin A construct (Figure 2a ) was generated and transfected into HEK293 cells. Three clones that were stably expressing napsin A (napsin 1, napsin 2 and napsin 3) were isolated, together with two clones transfected with empty vector as a control. We also generated a mutation in the catalytic site by changing Asp283 into an Asn (napsin D283N ) (Figure 2a ). The mutant was transfected into HEK293 cells and clones stably expressing the mutant were selected (clones napsin D283N 21 and napsin D283N 22) . The level of expression of wild-type and mutated napsin A was comparable in these clones (Figure 2b ). Napsin A expression was also analyzed by immunofluoresence staining and we found 499% of the cells to stain positive. Cells expressing the mutant had similar population doubling times as napsin A transfectants and significantly (Po0.001) longer time than control cells (25.3±1.3 and 24.9±1.5 h for control 1 and 2; 29.2±0.4 and 27.2±1.6 h for napsin 1 and 2; 29.4±3.5 and 31.4±1.2 h for napsin D283N 21 and 22).
We examined whether the D283N mutation resulted in loss of catalytic activity and whether the mutation altered the processing and intracellular localization of the enzyme. The N-terminal propeptide of proSP-B has been reported to be a physiological substrate of napsin A. 16 Mutation of the catalytic aspartic acid residue D283 resulted in loss of the ability of napsin to cleave a truncated form of recombinant proSP-B (SP-B DC ) (Figure 3a) . Napsin A is synthesized in a proform and processed into the mature form by removal of its N-terminal prosegment. The mature protein is glycosylated in some or all of the three potential N-linked oligosaccharide attachment sites. 25 Wild-type napsin A and napsin D283N both migrated as 41 kDa proteins in SDS-PAGE (Figure 3b) . Deglycosylation by endoglycosidase F resulted in a decrease in the molecular weight to 38 kDa (Figure 3b ), in agreement with the estimated molecular weight (38.9 kDa) of mature napsin A. These results suggest that wild-type and mutant napsins were glycosylated in the same way. As inactivation of the catalytic site did not affect processing, maturation of napsin A is not dependent on intramolecular autocatalysis in HEK293 cells.
Finally, to examine if the D293N mutation affects the intracellular localization of napsin A, we generated an expression vector expressing wild-type napsin A fused with GFP. This vector was transfected into cells expressing either wildtype or mutated napsin A containing an HA tag. As shown in Figure 3c , mutated napsin A (stained with a Cy3-labeled antibody) colocalized with wild-type napsin A (GFP), suggesting that mutation in the catalytic site did not affect the localization of napsin A.
Napsin A Expression Leads to Tube Formation and Reduced Colony Formation in Soft Agar Independent of Its Catalytic Activity
The phenotype of the HEK293 cell clones expressing wildtype or mutant napsin A was examined in detail. The cells of different clones were grown in collagen gels for 2 weeks. Phase-contrast microscopy showed that napsin A-transfected cells formed tube-like structures with branching morphology in the collagen gels whereas control cells did not (Figure 4a ). Cells expressing napsin D283N also formed tube-like structures in collagen (not shown). The difference in the organization of the cells in the collagen gels was more clearly discerned after DAPI staining of cell nuclei (Figure 4b ). Napsin A-expressing cells formed cyst-like structures whereas control cells did not (Figure 4b and c) . Interestingly, napsin A staining was observed in the center of the cyst-like structures (Figure 4c ). These results suggest that napsin A promotes differentiation of HEK293 cells.
To determine whether the change in phenotype was associated with an altered ability for anchorage-independent growth, the ability of these cell lines to form colonies in soft agar was determined. All three clones of napsin A-expressing cells formed fewer colonies in soft agar than control clones ( Figure 5 ). Cells expressing napsin D283N formed a similar number of colonies as cells expressing wild-type napsin, and fewer than control ( Figure 5 ). The catalytic activity of napsin A therefore does not appear to be required for suppression of colony formation in soft agar.
Tumor Growth In Vivo
Tumor formation of cells expressing wild-type or mutated napsin A was examined in SCID mice. Injection of HEK293 cells transfected with empty vector resulted in tumors first detected between days 30 and 36 ( Figure 6 ). All injections resulted in tumor formation. The wild-type napsin A-expressing clones formed tumors with delayed onsets (day 70 to day 133). Six injections out of 10 in this group (2 from napsin 1 and 4 from napsin 2) did not result in detectable (a) Recombinant SP-B DC was synthesized in the baculovirus system, and napsin A and its mutant were expressed in HEK293 cells. Recombinant SP-B DC was incubated with napsin A or its mutant at pH 4.7 at 371C for 2 h. Napsin A cleaved SP-B DC whereas napsin D283N had lost the catalytic activity. 
DISCUSSION
Napsin mRNA expression is detected in mesonephric tubules of the mouse kidney at embryonic day 13. 19 Expression is observed in proximal convoluted tubules in the mouse 19 and human (this study). Despite the fact that renal cell carcinomas arise mostly from proximal convoluted tubules, 26 napsin A mRNA was detected only in one of 29 cases of renal cell carcinoma. This result is consistent with a previous report where no staining of napsin A was observed in 15 cases of renal cell carcinoma by immunohistochemistry. 15 A similar pattern of napsin expression during embryogenesis and carcinogenesis is observed in the lung. Napsin expression is detected at the onset of differentiation of type II cells at embryonic day 15 19 and is maintained in type II cells in the adult. 11, 12 Napsin A is expressed in well-differentiated lung adenocarcinomas, whereas expression is weak in poorly differentiated tumors. 15, 16 Napsin A has no known role in kidney. The pattern of napsin A expression during development and carcinogenesis raises the possibility that napsin A may have a function in inducing and/or maintaining the differentiated state. We engineered HEK293 kidney cells to express napsin A cDNA. Napsin A is strongly expressed in normal kidney and lung tissue; in the lung, napsin A was originally identified as a strong spot (TA02) on two-dimensional gels 27 and kidney Animals with large tumors were killed in accordance with local ethical committee regulations.
Napsin A suppresses tumor growth T Ueno et al expression has also been reported to be strong. 10 We were therefore not concerned that stably transfected cells would express unphysiological levels of the protein. Napsin A-transfected HEK293 cells had somewhat (10-20%) longer population doubling times compared with vector-transfected cells. Interestingly, when napsin A-expressing cells were grown in three-dimensional collagen gels, they were found to form cyst-like structures. Induction of this phenotype was not dependent on the catalytic activity of napsin A. Although the mechanism(s) involved is presently unknown, this result suggests that napsin A may have a function in the differentiation of kidney epithelial cells.
Napsin A-expressing HEK293 cells showed a reduced capacity for anchorage-independent growth. Furthermore, napsin A-expressing cells formed tumors in SCID mice with a lower efficiency and with a delayed onset. This finding is consistent with an association of napsin A in maintaining a higher degree of differentiation of kidney epithelial cells. The inhibition of anchorage-independent growth and tumor formation was found to be independent of the catalytic activity of napsin.
Previous studies have implicated aspartic proteases in tumorigenesis. Cathepsin D has been shown to stimulate cancer growth in vitro and in vivo.
28,29 Downregulation of cathepsin D by antisense methods leads to decreased tumorigenicity of breast cancer cells in nude mice. 30 Interestingly, a mutated cathepsin D lacking its catalytic activity stimulates cancer cell proliferation as efficiently as the wild type. 6 It has been hypothesized that stimulation of cancer growth by cathepsin D is mediated by an as yet unknown receptor. 6 As the overall structure of napsin A is similar to that of cathepsin D, one possible mechanism of tumor suppression by napsin A is that napsin A may antagonize the growth stimulatory effect of a hypothetical cathepsin D receptor.
The localization of the catalytic mutant was found to be indistinguishable from that of wild-type napsin A. Furthermore, the mutant enzyme was processed and glycosylated in the same way as wild-type napsin A. Different activation mechanisms have been described for aspartic proteases, including autoactivation (pepsinogen 31 ), activation in trans by other enzyme(s) (prorenin 32 ) and a combination of autoactivation and assisted cleavage (procathepsin D 33 ). A previous study showed that purified napsin A does not cleave a 15-amino-acid peptide covering its own propeptide cleavage site. 25 This suggested that napsin A is not activated by autoactivation. Our data directly show that processing of napsin A is not dependent on intramolecular autocatalysis, at least not in HEK293 cells.
In conclusion, we showed that napsin A suppressed tumor growth in HEK293 cells independent of its catalytic activity. Further insight into the mechanim(s) involved may help in defining targets for therapeutic intervention in renal cancer. One possible strategy would be to reintroduce napsin A into cells. Other strategies could involve design of drugs or other agents that mimic the activity of napsin A. It is important to further elucidate the mechanisms of tumor suppression by napsin A to better understand the biology of kidney cancer development.
